Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:37 AM
Ignite Modification Date: 2025-12-25 @ 12:37 AM
NCT ID: NCT04801667
Eligibility Criteria: Inclusion Criteria: 1. Adults over 18 years old; 2. Time after transplantation greater than 3 months; 3. Time after treatment with anti-thymocyte globulin longer than 4 weeks; 4. Able and willing (in the investigator's opinion) to comply with all study requirements; 5. Provide written informed consent Exclusion Criteria: 1. Planned receipt of any vaccine (authorized or experimental), within 30 days before and after vaccination; 2. Prior receipt of an experimental or authorized vaccine with the possibility of impacting the interpretation of the study data (for example, vectorized vaccines by Adenovirus, any vaccines against coronavirus); 3. Administration of immunoglobulins and / or any blood products in the three months prior to the planned administration of the candidate vaccine; 4. Any history of angioedema or anaphylaxis; 5. Pregnancy, lactation or willingness / intention to become pregnant during the study; 6. Diagnosis or current treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ); 7. History of severe psychiatric illness that possibly affects your participation in the study; 8. Hemorrhagic disorder (eg, factor deficiency, coagulopathy or platelet disorder) or a previous history of significant bleeding or hematoma after IM injections or venipuncture; 9. Continued use of anticoagulants, such as coumarins and related anticoagulants (for example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban, dabigatran and edoxaban); 10. Current suspected or known addiction to alcohol or drugs.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 100 Years
Study: NCT04801667
Study Brief:
Protocol Section: NCT04801667